Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model
From MaRDI portal
Publication:2437023
DOI10.1016/j.mbs.2013.07.020zbMath1308.92047OpenAlexW2070186352WikidataQ51175423 ScholiaQ51175423MaRDI QIDQ2437023
Jeng-Huei Chen, Hsing Paul Luh, Ya-Hui Kuo
Publication date: 27 February 2014
Published in: Mathematical Biosciences (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1016/j.mbs.2013.07.020
Related Items
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Unnamed Item
- The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics
- The worst drug rule revisited: mathematical modeling of cyclic cancer treatments
- Tutorials in mathematical biosciences III. Cell cycle, prolifereation, and cancer.
- Role of optimal control theory in cancer chemotherapy
- A model for the resistance of tumor cells to cancer chemotherapeutic agents
- A theoretical analysis of interval drug dosing for cell-cycle-phase- specific drugs
- Time-continuous branching walk models of unstable gene amplification
- Singularity of optimal control in some problems related to optimal chemotherapy
- The effect of heterogeneity on optimal regimens in cancer chemotherapy
- A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy
- Sufficient conditions for relative minima of broken extremals in optimal control theory
- Optimal bang-bang controls for a two-compartment model in cancer chemotherapy
- Cancer chemotherapy optimization under evolving drug resistance.
- The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling
- Stochastic modeling of drug resistance in cancer
- The dynamics of gene amplification described as a multitype compartmental model and as a branching process
- The High Order Maximal Principle and Its Application to Singular Extremals
- ANALYSIS OF A CELL-CYCLE SPECIFIC MODEL FOR CANCER CHEMOTHERAPY